Overview

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2009-02-03
Target enrollment:
Participant gender:
Summary
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Rosiglitazone